New triple therapy aims to tame type 2 diabetes

NCT ID NCT07026968

Ongoing Disease control Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether adding two new drugs—prusogliptin and dapagliflozin—to standard metformin can improve blood sugar control in adults with type 2 diabetes. About 815 participants who are not well-controlled on metformin alone will receive either the triple combination or a placebo plus metformin. The main goal is to see if the combo lowers HbA1c (a key blood sugar measure) more effectively after 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: prusogliptin, dapagliflozin, and metformin
What this could lead to: If successful, this triple-drug combination could offer a new, more effective option for managing blood sugar in people with type 2 diabetes who don't get enough help from metformin alone.
What could go wrong: This is a phase 3 trial, but results are not yet available. The combination may not prove significantly better than existing treatments, and side effects from multiple drugs could be a concern.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES

Contacts and locations

Locations

No. 896, Zhongshan East Road, High-tech Industrial Development Zone

Shijiazhuang, Hebei, 050035, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.